Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: K-877 Clear all
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

NCT03001817
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
K-877, Fenofibrate, Placebo (for K-877), Placebo (for Fenofibrate)
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
110
States / cities
Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study in Health Adult Volunteers

NCT02273986
View directory record Official record
Conditions
Healthy
Interventions
Digoxin, K-877
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

NCT05327127
View directory record Official record
Conditions
NASH
Interventions
K-877-ER, CSG452, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
37
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lincoln, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study in Healthy Adult Volunteers

NCT02276001
View directory record Official record
Conditions
Healthy
Interventions
K-877, Cyclosporine
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Assess the Effects of Multi Dose Clopidogrel on the Pharmacokinetics of Single-Dose K-877 in Healthy Adult Volunteers

NCT02922465
View directory record Official record
Conditions
Healthy
Interventions
K-877, Clopidogrel
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult Volunteers

NCT02719431
View directory record Official record
Conditions
Healthy
Interventions
Warfarin, K-877
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult Volunteers

NCT04237597
View directory record Official record
Conditions
Healthy
Interventions
K-877, CSG452
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 2, 2026, 1:52 AM EDT
Terminated Phase 3 Interventional Results available

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

NCT03071692
View directory record Official record
Conditions
Type2 Diabetes, Dyslipidemia
Interventions
K-877, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
242
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 192 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR

NCT04447820
View directory record Official record
Conditions
Dyslipidemia
Interventions
K-877-ER (Dose A), K-877-ER (Dose B), K-877-IR
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
12
States / cities
Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

NCT03011450
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
K-877, Fenofibrate, Placebo (for K-877)
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
129
States / cities
Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study in Healthy Adult Volunteers

NCT02275988
View directory record Official record
Conditions
Healthy
Interventions
K-877, Clarithromycin
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Food Effect of K-877 in Healthy Adult Volunteers

NCT04742218
View directory record Official record
Conditions
Healthy
Interventions
K-877
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2021 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452

NCT05722262
View directory record Official record
Conditions
Healthy
Interventions
K-001, K-877-ER, CSG452
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough Corrected QT Interval Trial

NCT02073084
View directory record Official record
Conditions
Dyslipidemia
Interventions
K-877 Low Dose, Moxifloxacin, Placebo, K-877 High Dose
Drug · Other
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare the Pharmacokinetic of K-877 Controlled Release (CR) and Immediate Release (IR) Tablets in Healthy Adults.

NCT03702673
View directory record Official record
Conditions
Healthy
Interventions
K-877 CR Tablet A, K-877 CR Tablet B, K-877 CR Tablet E, K-877 IR Tablet
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study in Healthy Adult Volunteers

NCT02275975
View directory record Official record
Conditions
Healthy
Interventions
K-877, Fluconazole
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study in Healthy Adult Volunteers

NCT02275962
View directory record Official record
Conditions
Healthy
Interventions
K-877, Rifampin
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 2, 2026, 1:52 AM EDT